| Literature DB >> 20844762 |
Sofía Feliziani1, Adela M Luján, Alejandro J Moyano, Claudia Sola, José L Bocco, Patricia Montanaro, Liliana Fernández Canigia, Carlos E Argaraña, Andrea M Smania.
Abstract
Survival of Pseudomonas aeruginosa in cystic fibrosis (CF) chronic infections is based on a genetic adaptation process consisting of mutations in specific genes, which can produce advantageous phenotypic switches and ensure its persistence in the lung. Among these, mutations inactivating the regulators MucA (alginate biosynthesis), LasR (quorum sensing) and MexZ (multidrug-efflux pump MexXY) are the most frequently observed, with those inactivating the DNA mismatch repair system (MRS) being also highly prevalent in P. aeruginosa CF isolates, leading to hypermutator phenotypes that could contribute to this adaptive mutagenesis by virtue of an increased mutation rate. Here, we characterized the mutations found in the mucA, lasR, mexZ and MRS genes in P. aeruginosa isolates obtained from Argentinean CF patients, and analyzed the potential association of mucA, lasR and mexZ mutagenesis with MRS-deficiency and antibiotic resistance. Thus, 38 isolates from 26 chronically infected CF patients were characterized for their phenotypic traits, PFGE genotypic patterns, mutations in the mucA, lasR, mexZ, mutS and mutL gene coding sequences and antibiotic resistance profiles. The most frequently mutated gene was mexZ (79%), followed by mucA (63%) and lasR (39%) as well as a high prevalence (42%) of hypermutators being observed due to loss-of-function mutations in mutL (60%) followed by mutS (40%). Interestingly, mutational spectra were particular to each gene, suggesting that several mechanisms are responsible for mutations during chronic infection. However, no link could be established between hypermutability and mutagenesis in mucA, lasR and mexZ, indicating that MRS-deficiency was not involved in the acquisition of these mutations. Finally, although inactivation of mucA, lasR and mexZ has been previously shown to confer resistance/tolerance to antibiotics, only mutations in MRS genes could be related to an antibiotic resistance increase. These results help to unravel the mutational dynamics that lead to the adaptation of P. aeruginosa to the CF lung.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20844762 PMCID: PMC2937033 DOI: 10.1371/journal.pone.0012669
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Genotypic and morphotypic characterization of the 38 P. aeruginosa CF isolates.
| Patient | Isolate | Genotype | Phenotype | Source | Year of isolation | ||||
| Mucoidity | SCV | Pigmentation | Iridescence | Mutation Frequency | |||||
| 1 | a | ND | + | - | - | - |
| HNC | 2004 |
| b | A1 | + | - | - | - |
| HNC | 2007 | |
| c | A1 | + | + | - | - | (2.7±1.9)×10−9 | HNC | 2007 | |
| 2 | a | A1 | - | + | - | + |
| HNC | 2007 |
| b | A2 | + | - | - | - | (1.7±1.4)×10−9 | HNC | 2007 | |
| 3 | a | B1 | + | - | - | - |
| HNC | 2004 |
| b | B1 | - | + | - | - |
| HNC | 2007 | |
| c | B1 | + | - | + (green) | - |
| HNC | 2008 | |
| 4 | a | C1 | + | - | - | - | (2.8±1.4)×10−8 | HNC | 2007 |
| b | C1 | - | - | - | - | (9.0±6.3)×10−9 | HNC | 2007 | |
| 5 | a | D1 | + | - | - | - |
| HNC | 2007 |
| 6 | a | E1 | - | - | - | - | (6.4±4.5)×10−9 | HNC | 2007 |
| 7 | a | Q1 | - | - | + (green) | - | (2.9±0.8)×10−8 | HNC | 2007 |
| 8 | a | R1 | + | - | - | - | (2.2±0.5)×10−8 | HNC | 2007 |
| 9 | a | F1 | + | - | - | - |
| HNC | 2004 |
| 10 | a | L1 | + | + | - | - |
| HNC | 2008 |
| 11 | a | N1 | + | - | - | - | (1.0±0.5)×10−9 | HNC | 2008 |
| 12 | a | O1 | + | - | - | - | (3.9±2.1)×10−9 | HCN | 2008 |
| 13 | a | G1 | - | - | - | + | (4.1±0.3)×10−9 | HABA | 2006 |
| 14 | a | H1 | - | - | + (green) | - | (5.0±3.2)×10−9 | HABA | 2006 |
| 15 | a | S1 | - | + | + (red) | - | (1.1±0.6)×10−7
| HABA | 2006 |
| 16 | a | I1 | + | - | + (green) | - | (6.7±1.8)×10−9 | HABA | 2006 |
| 17 | a | J1 | - | - | + (green) | - | (2.6±1.5)×10−9 | HABA | 2006 |
| b | J1 | + | - | - | - |
| HABA | 2006 | |
| 18 | a | K1 | + | + | - | - | (5.5±2.1)×10−9 | HABA | 2006 |
| b | K1 | - | + | - | - | (2.9±2.3)×10−8 | HABA | 2006 | |
| c | K1 | + | - | - | - | (1.2±1.1)×10−9 | HABA | 2008 | |
| d | K1 | - | + | - | + |
| HABA | 2008 | |
| 19 | a | M1 | + | - | - | - |
| HABA | 2006 |
| 20 | a | P1 | + | - | + (green) | - | (9.0±4.0)×10−10 | HABA | 2008 |
| b | P1 | - | - | + (green) | - |
| HABA | 2008 | |
| 21 | a | T1 | + | + | - | - |
| HABA | 2008 |
| b | T1 | - | + | - | + |
| HABA | 2008 | |
| 22 | a | U1 | + | - | - | - |
| HABA | 2008 |
| 23 | a | V1 | - | - | + (green) | - | (1.9±1.3)×10−9 | HABA | 2008 |
| 24 | a | W1 | - | - | - | + | (4.0±2.0)×10−10 | HABA | 2008 |
| 25 | a | X1 | - | - | - | + | (1.1±0.2)×10−7
| HABA | 2008 |
| 26 | a | Y1 | + | - | - | - | (2.3±1.7)×10−9 | HABA | 2008 |
All isolates were genotyped by PFGE using the SpeI enzyme.
Mutation frequency was measured as the occurrence of spontaneous resistance to rifampin 100 µg/ml.
Isolates 15a and 25a with mutation frequencies nearly under the breakpoint (≥2×10−7) were discarded to be mutS or mutL deficient strains by gene sequencing (see Table 2).
SCV, Small Colony Variant; ND, not determined; HNC, Hospital de Niños de Córdoba; HABA, Hospital Alemán de Buenos Aires.
Those isolates with mutation frequencies ≥2×10−7 were defined as hypermutators and indicated by bold type.
Mutation frequencies for PAO1 reference strain and MPAOMS and MPAOML hypermutator strains were (2.4±1.3)×10−8, (2.8±1.6)×10−6 and (1.3±0.6)×10−6 respectively.
Mutations in the mucA, lasR and mexZ genes of the 38 P. aeruginosa CF isolates.
| Isolate |
|
|
| MRS genes |
| 1a | C→T at 349 (TAA at 349) | A→G at 587 (E196G) | C→G at 151 (H51D) |
|
| 1b | C→T at 349 (TAA at 349) | A→G at 587 (E196G) | C→G at 151 (H51D) |
|
| 1c | 1 bp del at 426 (TGA at 440) | NF | 1 bp del at 261 (TAA at 332) | ND |
| 2a | NF | 1 bp del at 308 (TGA at 341) | 1 bp del at 242 (TAA at 332) |
|
| 2b | 1 bp del at 426 (TGA at 440) | NF | 1 bp del at 261 (TAA at 332) | ND |
| 3a | 1 bp del at 426 (TGA at 440) | NF | NF |
|
| 3b | 1 bp del at 426 (TGA at 440) | NF | NF |
|
| 3c | NF | NF | NF |
|
| 4a | 1 bp del at 426 (TGA at 440) | NF | 10 bp del at 595 | ND |
| 4b | 1 bp del at 426 (TGA at 440) | NF | 10 bp del at 595 | ND |
| 5a | 1 bp del at 426 (TGA at 440) | NF | NF |
|
| 6a | NF | NF | 2 bp del at 60 | ND |
| 7a | 1 bp del at 426 (TGA at 440) | A→G at 626 (N209S) | T→C at 110 (L37P) | ND |
| 8a | C→T at 352 (TAG at 352) | NF | 10 bp del at 184 | ND |
| 9a | C→T at 349 (TAA at 349) | 2 bp del at 602 (TAG at 617) | 14 bp del at 340 |
|
| 10a | C→T at 340 (TAG at 340) | NF | 11 bp del at 328 |
|
| 11a | 1 bp del at 426 (TGA at 440) | NF | 1 bp deletion at 609 | ND |
| 12a | NF | NF | NF | ND |
| 13a | NF | NA | A→G at 633 (TAG 211 W) | ND |
| 14a | NF | NF | A→G at 34 (T12A); G→A at 44 (G15D) | ND |
| 15a | NF | NF | NA | NF |
| 16a | 1 bp del at 201 (TGA at 284) | NF | 11 bp del at 365 | ND |
| 17a | NF | NF | 38 bp del at 417 | ND |
| 17b | NF | NF | 13 bp del at 340 |
|
| 18a | 1 bp del at 339 (TGA at 386) | NF | 4 bp del at 595 | ND |
| 18b | 1 bp del at 339 (TGA at 386) | NF | 4 bp del at 595 | ND |
| 18c | 1 bp del at 430 (TGA at 440) | NF | 15 bp del at 60 (ΔRVFLE at 22) | ND |
| 18d | G→T at 421 (TAG at 421) | C→T at 617 (A206V) | NF |
|
| 19a | 1 bp del at 426 (TGA at 440) | NF | 368 bp del at 248 |
|
| 20a | C→T at 367 (TAG at 367) | T→G at 645 (I215M) | C→T at 187 (C63R) | ND |
| 20b | NF | T→G at 645 (I215M) | C→T at 187 (C63R); C→T at 283 (TAG at 283) |
|
| 21a | NF | C→T at 221 (P74L) | 21 bp del at 631 |
|
| 21b | NF | C→T at 221 (P74L) | 21 bp del at 631 |
|
| 22a | 1 bp del at 358 (TGA at 386) | C→T at 280 (TAG at 280) | 12 bp del at 425 (ΔRAVE at 143; R142Q) |
|
| 23a | G→C at 304 (G102R) | A→G at 575 (K192R) | T→G at 413 and C→A at 414 (L150R); 7 bp del at 451 | ND |
| 24a | NF | C→A at 317 (TGA at 315) | C→A at 494 (TAG at 493) | ND |
| 25a | NF | A→T at 697 (N233Y) | NF | NF |
| 26a | 1 bp del at 201 (TGA at 284) | NF | 12 bp del at 383 (ΔPLEK at 128) | ND |
NF, no mutation found; ND, not determined; NA, not PCR amplified; del, deletion; ins, insertion; dup, duplication.
Figure 1Mutational spectra of mucA, lasR, mexZ and MRS genes observed in P. aeruginosa isolates obtained from Argentinean CF patients.
Pie charts indicate the observed percentage for each kind of mutation respect to the total number of mutations occurring in (A) mucA, (B) lasR, (C) mexZ and (D) MRS genes. The analyses on MRS genes include mutations observed in mutS and mutL.
Figure 2Distribution of the number of mutations among mucA, lasR and mexZ genes in hypermutator and nonmutator isolates.
The number of mutations occurring in mucA (blue bars), lasR (green bars) and mexZ (red bars) is expressed as a percentage respect to the total number of mutations found in hypermutator and nonmutator isolates. Above the bars, the total number of mutations per isolate for the hypermutator and nonmutator subpopulations is indicated.
Antibiotic disk diffusion test and quantification of the resistant mutant subpopulations of the 38 P. aeruginosa CF isolates.
| Isolate | MRS genes | Ceftazidime | Ciprofloxacin | Imipenem | Meropenem | Tobramycin | |||||
| DD | RMS | DD | RMS | DD | RMS | DD | RMS | DD | RMS | ||
| 1a | - | S | +++ | S | ++ | S | +++ | S | +++ | S | ++ |
| 1b | - | S | +++ | I | ++ | S | +++ | S | +++ | R |
|
| 1c | + | S | ++ | S | - | S | - | S | ++ | S | - |
| 2a | - | R |
| R |
| S | +++ | S | +++ | S | +++ |
| 2b | + | S | + | S | - | S | - | S | + | S | - |
| 3a | - | I | ++ | I | - | S | +++ | S | +++ | I | +++ |
| 3b | - | R |
| I | ++ | I | +++ | S | +++ | I | +++ |
| 3c | - | S | +++ | S | +++ | S | +++ | S | +++ | S | ++ |
| 4a | + | S | - | S | - | S | - | S | - | S | - |
| 4b | + | S | - | S | - | S | - | S | - | S | - |
| 5a | - | S | - | R |
| S | ++ | S | +++ | S | + |
| 6a | + | S | - | S | - | S | - | S | - | S | - |
| 7a | + | S | - | I | - | S | - | S | - | S | - |
| 8a | + | S | - | R |
| S | +++ | S | +++ | S | - |
| 9a | - | S | ++ | S | +++ | S | +++ | S | +++ | S | +++ |
| 10a | - | S | ++ | S | ++ | S | +++ | S | - | S | +++ |
| 11a | + | S | - | S | - | S | - | S | - | R |
|
| 12a | + | S | - | S | - | S | - | S | - | S | - |
| 13a | + | S | - | R |
| S | - | S | - | R |
|
| 14a | + | S | - | S | - | S | - | S | - | S | - |
| 15a | + | S | - | S | - | S | - | S | - | S | - |
| 16a | + | S | - | S | - | S | - | S | - | S | - |
| 17a | + | S | - | I | - | R |
| I | - | S | - |
| 17b | - | S | - | S | - | I | +++ | S | ++ | S | + |
| 18a | + | S | - | S | - | S | - | S | - | S | - |
| 18b | + | S | - | R |
| S | - | S | - | S | - |
| 18c | + | S | - | S | - | S | - | S | - | S | - |
| 18d | - | S | +++ | R |
| R |
| S | +++ | R | ++ |
| 19a | - | R |
| R |
| R |
| R |
| R |
|
| 20a | + | S | - | S | - | S | - | S | - | S | - |
| 20b | - | S | +++ | R |
| R |
| S | +++ | S | +++ |
| 21a | - | S | +++ | R |
| S | ++ | S | +++ | S | +++ |
| 21b | - | S | +++ | R |
| S | +++ | S | +++ | S | +++ |
| 22a | - | S | - | S | - | S | ++ | S | +++ | S | +++ |
| 23a | + | S | - | S | - | S | - | S | ++ | S | - |
| 24a | + | S | - | S | - | S | - | S | - | S | - |
| 25a | + | S | - | S | - | S | - | S | - | S | - |
| 26a | + | S | - | S | - | S | - | S | - | S | - |
MRS genes was considered positive (+) when the sequences of mutS and mutL genes were wild type and negative (−) when were mutated.
DD, diffusion diameter zone; RMS, resistant mutant subpopulation: +<10 mutants; ++ 10 to 100 mutants; +++ >100 mutants.
Zone diameter interpretative criteria was according to CLSI: S, susceptible; I, intermediate resistance; R, resistant.
*lack of diffusion zone that prevents the resistant mutant subpopulation to be quantified.
Figure 3Association between antibiotic resistance and inactivation of mucA, lasR and mexZ.
(A) Differences in antibiotic resistance in the P. aeruginosa isolates harboring mutations in mucA (mucA-) respect to those without mutations in mucA (mucA+). Data is expressed as the percentage of resistant isolates to ceftazidime, ciprofloxacin, imipenem, meropenem and tobramycin in mucA- and mucA+ isolates. (B) The same analysis was carried out in lasR- and lasR+ isolates and (C) mexZ- and mexZ+ isolates. In the three genes, the observed differences were not significant (Fisher's exact test) for any of the tested antibiotics.
Bacterial strains, plasmids and primers used in this study.
| Genotype, relevant characteristics, or sequence (5′-3′) | Source or reference | |
| Strains | ||
|
| ||
| PAO1 | wild-type; phototropic |
|
| MPAOMS |
|
|
| MPAOML |
|
|
| Plasmids | ||
| pMC5- | pBBR1MCS-5 carrying |
|
| pMC5- | pBBR1MCS-5 carrying |
|
| Primers | ||
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
Tcr, tetracycline resistance; Gmr, gentamicin resistance.